rs1175544 — PPARG PPARG rs1175544

PPARG rs1175544 — Weight Loss Variation in the Master Fat-Cell Regulator

PPARG encodes Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
PPARγ is a nuclear receptor and transcription factor that acts as the master regulator of adipocyte differentiation (fat cell formation) and whole-body insulin sensitivity, the protein that determines how efficiently precursor cells develop into mature fat cells and how sensitively those cells respond to insulin. It is also the molecular target of thiazolidinedione²² thiazolidinedione
Thiazolidinediones (e.g., pioglitazone, rosiglitazone) bind and activate PPARγ, improving insulin sensitivity in type 2 diabetes treatment drugs used to treat type 2 diabetes. rs1175544 sits in intron 5 of PPARG (NM_005037.7:c.1181-8353C>T) — it does not alter the PPARγ protein sequence itself but lies in a regulatory region that may influence transcript abundance or splicing efficiency in metabolically active tissues.

The Mechanism

As an intronic variant, rs1175544 exerts its effects through regulatory mechanisms rather than protein-coding changes. Intronic variants in PPARG can alter transcription factor binding sites, affect local chromatin accessibility, or act as markers in linkage disequilibrium³³ linkage disequilibrium
Linkage disequilibrium (LD) means two variants are inherited together so frequently that one can serve as a proxy marker for the other's functional effect with nearby functional variants. rs1175544 sits in a cluster of PPARG intronic SNPs — including the neighboring rs1175543 — that tag a haplotype block spanning intron 4–5 of the gene. Changes in PPARγ transcriptional activity in adipose and hepatic tissue affect the rate of adipogenesis, alter free fatty acid flux, and modulate insulin signaling through effects on GLUT4 translocation and adipokine secretion.

The Evidence

The primary association with weight loss comes from a study by Matsuo et al.⁴⁴ study by Matsuo et al.
Matsuo T et al. PPARG genotype accounts for part of individual variation in body weight reduction in response to calorie restriction. Obesity (Silver Spring), 2009, which genotyped 8 PPARG variants in 95 middle-aged Japanese women (BMI ≥25 kg/m²) undergoing a structured 14-week calorie restriction intervention (1,200 kcal/day). Body weight decreased by approximately 7.7 kg (11.3%) on average. Among all SNPs tested, rs1175544 showed the strongest association with weight reduction (p=0.004), with the genotype accounting for 7% of total weight loss variance in multiple regression. Notably, no association was found between these SNPs and changes in coronary heart disease risk factors — suggesting the variant's metabolic effect is specific to weight loss response rather than broad cardiovascular risk.

A larger study by Imaizumi et al.⁵⁵ larger study by Imaizumi et al.
Imaizumi T et al. Effect of dietary energy and polymorphisms in BRAP and GHRL on obesity and metabolic traits. Obes Res Clin Pract, 2018 included rs1175544 in an 8-SNP PPARG panel assessed in 5,112 Japanese male workers, examining interactions between dietary energy intake and metabolic phenotypes. The study's primary significant results highlighted other genes (BRAP, GHRL), and rs1175544's independent contribution was not statistically significant in this broader population, suggesting the weight loss signal may be context-dependent or population-specific.

A secondary observation from Sadarangani et al.⁶⁶ Sadarangani et al.
Sadarangani SP et al. Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons. Hum Vaccin Immunother, 2016 found rs1175544 among three PPARG SNPs significantly associated with baseline 25-(OH)D levels (p=0.03), consistent with established links between PPARγ pathway activity and vitamin D metabolism.

The overall evidence for rs1175544 specifically remains at the emerging level: the primary weight loss finding comes from a single small study (n=95) in a single population (Japanese women), and the effect has not been replicated in a large independent cohort.

Practical Actions

For CT and TT carriers, the available data suggest that individual response to calorie restriction may diverge from population averages — the genotype accounted for 7% of variance, which is meaningful at the individual level even if modest in absolute terms. Given that PPARG intronic variants in this region form a haplotype block, the actionable strategy is to prioritize structured calorie deficit approaches and monitor actual weight trajectory over 4–8 weeks rather than relying on predicted outcomes from population norms. Consistent dietary energy tracking provides the feedback needed to adjust when individual response deviates from average.

Interactions

rs1175544 belongs to a PPARG intronic haplotype block that also includes rs1175543 and the neighboring rs3856806. These variants are in partial linkage disequilibrium and their combined haplotype context may matter more than any single variant alone. The well-established PPARG Pro12Ala variant (rs1801282) — which directly affects PPARγ protein activity and insulin sensitivity — is in a different region of the gene and likely acts independently of the intronic haplotype tagged by rs1175544. Another intronic PPARG variant, rs17036314, is specifically associated with physical activity modifying T2D conversion risk; its interaction with rs1175544 has not been studied.